NovaBridge Biosciences (NBP) Cash from Operations (2024 - 2025)
NovaBridge Biosciences (NBP) reported Cash from Operations of 14596000.0 for Q4 2025, down 33.31% year-over-year from 21886004.38 in Q4 2024, and down 893.69% quarter-over-quarter from 1839000.0 in Q3 2025.
NovaBridge Biosciences (NBP) Cash from Operations (2024 - 2025) Analysis & Trends
NovaBridge Biosciences (NBP) has 2 years of Cash from Operations data on file, last reported at 14596000.0 in Q4 2025.
- Cash from Operations for Q4 2025 came in at 14596000.0, down 33.31% year-over-year; the trailing twelve-month figure through Dec 2025 was 15284000.0 (changed N/A YoY), and the FY2025 annual result was 20597000.0, up 60.89% from the prior year.
- Cash from Operations retreated to 14596000.0 in Q4 2025 per NBP's latest filing, from 1839000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 8422000.0 in Q3 2024 and troughed at 14596000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | NovaBridge Biosciences | 328.19 Mn | 117.34 Mn | - | -14.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -14.60 Mn |
| Dec 31, 2025 | -14.60 Mn |
| Sep 30, 2025 | 1.84 Mn |
| Sep 30, 2025 | 1.84 Mn |
| Dec 31, 2024 | -10.95 Mn |
| Dec 31, 2024 | -10.95 Mn |
| Sep 30, 2024 | 8.42 Mn |
| Sep 30, 2024 | 8.42 Mn |